Clinical Trial – Study of Chiauranib in Relapsed/Refractory Non-Hodgkin’s Lymphoma – Non-Hodgkin’s Lymphoma

Chipscreen Biosciences, Ltd. is running a clinical trial to test a drug called Chiauranib to treat non-Hodgkin’s Lymphoma. Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B(Aurora B)、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin’s lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.

The drug is Chiauranib.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin’s Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study
Actual Study Start Date : May 9, 2017
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : May 2019

For enrollment please visit www.clinicaltrials.gov.

Leave a Reply